Avicanna Launches Major Cannabis Effects Study
Company Announcements

Avicanna Launches Major Cannabis Effects Study

Story Highlights

Avicanna (TSE:AVCN) has released an update.

Avicanna Inc., a biopharmaceutical company, has launched a significant study on medical cannabis with 1,000 Canadian patients to investigate its effects on conditions like pain, sleep, anxiety, depression, and epilepsy. Led by Dr. Hance Clarke, the study will leverage MyMedi.ca’s resources to enhance research and potentially integrate cannabis into the standard of care. The initiative is also supported by various licensed producers, including Avicanna’s own RHO Phyto product line.

For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAvicanna Secures $800K in Private Placement
TheFlyAvicanna announces medical cannabis real world evidence study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App